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ABSTRACT
Objective Frailty and heart failure (HF) are cross- 
sectionally associated. Published longitudinal data are very 
limited. We sought to investigate associations between 
frailty and incident HF.
Methods Prospective study of 1722 men, examined at 
age 72–91 years. Scores based on the Fried phenotype, 
Gill index and a novel frailty score, based on the Health 
Ageing and Body Composition Battery, incorporating 
slow walking speed, low chair- stand time and subjective 
difficulty with balance, were calculated. Associations 
between these scores and incident HF were analysed with 
Cox proportional hazard modelling.
Results 1445 men with frailty data and without prevalent 
HF were included. 99 developed HF (mean follow- up 6.1 
years). Men scoring 3/3 on our novel frailty score had 
elevated risk of incident HF (HR 2.77, 95% CI 1.25 to 
6.15), which persisted after adjustment for established 
risk factors and interleukin-6 (HR 3.14, 95% CI 1.35 to 
7.31). This risk remained increased, although attenuated, 
after excluding HF events within 2 years of baseline (HR 
2.05, 95% CI 0.61 to 6.92). The frailty phenotype showed 
a non- significant association with HF (age- adjusted HR 
1.92, 95% CI 0.99 to 3.73), which was further attenuated 
after adjustment for prevalent coronary heart disease and 
Body mass index (HR 1.60, 95% CI 0.81 to 3.15). Gill- type 
scores were weakly associated with HF risk after these 
adjustments (HR 1.31, 95% CI 0.47 to 3.70).
Conclusion In these older men, the combination of slow 
walk speed, low sit- stand time and balance problems 
were associated with high risk of incident HF, independent 
of established risk factors and inflammatory markers. 
However, undiagnosed HF at baseline may still be a 
confounder. There is a differential association between 
aspects of the frailty phenotype and incident HF.
INTRODUCTION
Frailty, from the Latin fragilis (brittle), 
describes multisystemic physiological 
dysfunction conferring vulnerability to rela-
tively minor health stressors. Frailty is strongly 
associated with older age and often co- occurs 
with multimorbidity.1
Heart failure (HF) and frailty frequently 
coexist.2 People with HF who are frail 
experience higher mortality rates, higher 
hospitalisation rates and greater disability.3 
The mechanistic features of HF and frailty 
overlap, with ageing, chronic inflammation, 
comorbidity and sarcopenia implicated in 
both, and when the two coexist, there seems 
to be a bidirectional relationship, with each 
worsening the effects of one other.4
Frailty and HF have been examined in many 
cross- sectional studies, but there is a paucity 
of longitudinal data, with a recent system-
atic review identifying only two longitudinal 
analyses of frailty and HF.5 In the Women’s 
Health Initiative Observational Study, a large 
cohort of women aged 65–79, the presence 
of HF showed no association with frailty risk 
at 3- year follow- up.6 Conversely, in the Health 
Ageing and Body Composition (HABC) Study 
cohort, among participants aged 70–79, frailty 
Key questions
What is already known about this subject?
 ► Heart failure (HF) and frailty are associated in cross- 
sectional studies, and probably share common 
pathophysiological determinants. Longitudinal data 
are very limited; only one published study has re-
ported an association between frailty and the de-
velopment of HF.
What does this study add?
 ► Frailty, as measured by the combination of slow 
gait speed, low chair- stand time and difficulty with 
balance, is associated with elevated risk of devel-
oping HF, even after adjusting for comorbidities, 
established risk factors and inflammation. Frailty as 
defined by the Fried frailty index showed a weaker 
association with HF risk. We found no associations 
between a score based on the Gill index and HF.
How might this impact on clinical practice?
 ► People who are frail should be considered at high-
er risk of developing HF. Further work might lead to 
frailty assessment, based on the criteria we describe 
here, being used as part of HF risk prediction scores. 
Interventions to prevent or ameliorate frailty might 
help to reduce the subsequent development of HF.
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at baseline in people was associated with increased risk of 
incident HF.7 This risk persisted despite adjustment for 
the HABC Risk score (based on age, heart rate, smoking 
status, fasting glucose, creatinine, systolic blood pressure 
and serum albumin), inflammatory markers, ankle arm 
index, incident coronary heart disease and competing 
mortality. Two measures of frailty were used: the HABC 
battery, a composite of gait speed, five serial chair stands, 
narrow walk time and standing balance8; and the Gill 
index, based on gait speed and chair stand tests.9
We have previously demonstrated cross- sectional asso-
ciations between cardiovascular risk factors and a frailty 
score based on the commonly used Fried frailty pheno-
type,10 11 which integrates exhaustion, unintentional 
weight loss, low physical activity, slow walking speed and 
low grip strength.
We; therefore, sought to determine whether frailty as 
measured by three different measures of frailty (based on 
Fried, Gill and HABC) is prospectively associated with HF 
risk in older men, allowing for potential confounders.
METHODS
British Regional Heart Study
The British Regional Heart Study is a prospective study 
of 7735 men, aged 40–59 at enrolment, drawn from one 
general practice in each of 24 British towns. Sampling 
aimed to reflect the socioeconomic structure of those 
towns. Over 99% of the participants were of White Euro-
pean ethnicity.
Initial screening took place from 1978 to 1980. This 
paper uses data from the 30- year examination, when 
men were aged 72–91 years. All surviving men in 2010–12 
(n=3137) were invited to attend a reassessment which 
included a questionnaire, physical examination, ECG 
and provision of a fasting blood sample.
Questionnaire data
All participants completed a questionnaire regarding their 
lifestyle, medical and medication history. Tobacco usage 
was categorised as: never- smokers, long- term ex- smokers 
(stopped smoking ≥10 years prior), recent ex- smokers 
(stopped smoking <10 years prior) and current smokers. 
Heavy alcohol use was defined as average consump-
tion of ≥42 UK units (1 unit=10 g) of alcohol per week. 
Items included self- report of walking pace (slow/steady 
average/fast), difficulty in keeping balance (yes/no), 
change in weight (decreased/increased/both increased 
and decreased/not changed/don’t know) and uninten-
tional weight loss.
Prevalent comorbidities
Prevalent HF, stroke (ischaemic or haemorrhagic) and 
myocardial infarction (MI) were defined as a confirmed 
doctor’s diagnosis prior to the baseline examination, 
based on primary care records. Prevalent diabetes 
mellitus was defined as either a physician- confirmed diag-
nosis of diabetes mellitus, or a fasting serum glucose of 
greater than 7 mmol/L.
Physical examination
Blood pressure was measured with an Omron sphygmo-
manometer twice in the right arm, with the subject seated 
and the arm supported. The mean of the two readings 
was used for analysis. With subjects in light clothing and 
without shoes, height was measured with a Harpenden 
stadiometer to the last complete 0.1 cm, and weight with 
a Tanita MA-418- BC body composition analyser (Tanita, 
Tokyo, Japan). Body mass index (BMI) was calculated 
as weight/(height)2 (kg/m2). Grip strength (in kilo-
grams) was measured using a Jamar Hydraulic Hand 
Dynamometer, with three measurements taken with each 
hand and the best of six used for the analysis. A walking 
test measured the time taken, in seconds, to walk 3 m at 
normal walking pace. A five- repetition sit- to- stand test 
was performed: participants were asked to move from 
a seated to a standing position five times in succession, 
avoiding the aid of hands and the time taken, in seconds, 
to perform this was recorded. Forced expiratory volume 
in 1 s (FEV1) was measured using a Vitalograph Compact 
II instrument with subjects standing, without nose clips. 
FEV1 was standardised to the average study height, 
1.71 m, using the formula: standardised FEV1=FEV1 × 
(1.71/height)2.
Electrocardiography
A twelve- lead resting ECG was recorded using a Siemens 
Sicard 460 instrument and classified using the Minne-
sota Coding scheme.12 ECG left ventricular hypertrophy 
(LVH) was defined as the presence of either Minnesota 
codes 3.1 or 3.3 (high amplitude R waves) plus evidence 
of left ventricular strain, defined as the presence of codes 
4.1 or 4.2 (ST depression) or codes 5.1 or 5.2 (T wave 
inversion). The presence of Q waves was defined by 
Minnesota codes 1.1, 1.2 and 1.3 (and subcodes) in any 
of the anterolateral, anterior or inferior/posterior sites. 
Atrial fibrillation (AF) was defined as Minnesota codes 
8.3.1 and 8.3.3.
Biomarker measurement
Fasting serum samples were obtained. Glucose was meas-
ured in a fluoride oxidase plasma sample and creatinine 
measured using enzymatic colorimetric assays. Estimated 
glomerular filtration rate (eGFR) was calculated using 
the Modification of Diet in Renal Disease (MDRD) equa-
tion.13 Plasma interleukin-6 (IL-6) was measured using 
ELISA (R&D systems, Oxon, UK). N- terminal pro- B- type 
natriuretic peptide (NT- pro- BNP) was measured by elec-
trochemiluminescence immunoassay (Roche Diagnos-
tics, Burgess Hill, UK).
Frailty scoring
Three different frailty scores were calculated for each 
participant. A score based on the Fried frailty phenotype11 
was calculated from five variables: unintentional weight 
loss (a decrease in self- reported weight that respondents 
felt was unintentional); exhaustion (answering ‘no’ to the 
question ‘Do you feel full of energy?’); weakness (lowest 
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fifth of grip strength distribution); low physical activity 
(self- report of being less active or much less active than 
an average man); and slow walking speed (lowest fifth 
of walking speed). Where measured walking speed was 
unavailable, self- report of low walking pace was used (self- 
report of walking speed, or being unable to walk more 
than a few steps, or <200 yards (approximately 180 m), or 
difficulty walking across a room), Participants with none 
of these features were defined as ‘robust’; with one or two 
as ‘pre- frail’; and with three or more as ‘frail’.
To aid comparisons to prior work, we calculated frailty 
scores analogous to the Gill index and HABC battery. The 
Gill index measures speed over 6 m (<0.6 m/s2=1 point) 
and ability to stand from a seated position with arms 
folded (unable=1 point). Our ‘Gill- like’ score assigned 
one point for walk speed <0.6 m/s2 over 3 m, and one 
point for inability to perform five chair- stands without 
use of hands (or inability to perform at all). A total score 
of 1 corresponds to ‘moderate’ frailty and 2 to ‘severe’ 
frailty.9
The HABC battery is a continuous composite score of 
performance on four tests: measured gait speed over 6 m, 
five serial chair stands, narrow walk over 6 m and timed 
standing balance over 30 s.8 Since we did not have direct 
measurements of narrow walk or balance time, we could 
not compute a continuous ratio score. We constructed a 
new interval score measure of frailty based on three vari-
ables: 3 m walk speed (1 point if <0.6 m/s, or if unable to 
do at all), time to perform five serial chair stands without 
use of hands (1 point if ≥18 s, if unable to do without 
hands or at all) and self- reported difficulty maintaining 
balance (1 point if answering ‘yes’ to the question ‘Do 
you currently have difficulty carrying out any of the 
following activities on your own as a result of a long term 
health problem—Keeping your balance?’). Cut- offs for 
walk time and sit- stand time were derived by visual inspec-
tion of scatter plots, showing inflection points at approx-
imately 0.6 m/s and 18 s respectively. This is henceforth 
referred to as the ‘novel’ score.
Exclusion criteria
Men with a diagnosis of HF at baseline were excluded from 
analysis, as were men without data on any of the three 
frailty scores. Analyses were handled using complete- 
case analysis at that step of the analysis: participants with 
missing values for any variable within that analytic step 
were excluded.
Follow-up
All men were followed up to June 2018 for cardiovas-
cular morbidity and mortality. Mortality was obtained via 
the National Health Service Register. Incident HF was 
defined as a confirmed doctor’s diagnosis of HF from 
primary care records, and verified, where possible, using 
clinical information from primary and secondary care 
records, as well as from death certificates with Interna-
tional Classification of Diseases (ICD)-9 code 428. Time 
to incident HF was the time between the baseline exami-
nation and confirmed doctor’s diagnosis of HF.
Statistical analysis
All statistical analyses were performed using SAS soft-
ware, V.9.4 of the SAS System for Windows.
Descriptive statistics were used to report sample char-
acteristics at baseline, with χ2 tests used for comparisons 
between groups for categorical variables. The t- tests were 
used for comparisons of normally distributed variables. 
Distributions for NT- pro- BNP and IL-6 were positively 
skewed. Geometric means were calculated for these vari-
ables and comparisons made using the Kruskal- Wallis 
test. These variables were natural log- transformed for 
further analysis.
Cox proportional hazard modelling was used to assess 
associations between frailty score group and the relative 
risk of incident HF over time, correcting for potential 
confounders. Non- frail groups were used as the reference.
Four stepwise analyses were performed to assess how 
associations between incident HF and frailty score atten-
uated with progressive adjustment. The initial model 
included frailty score and age as independent variables. 
The second model added prevalent MI and BMI. The 
third model added other known risk factors for HF: 
systolic blood pressure; diabetes mellitus; use of blood 
pressure lowering medication; FEV1; smoking status; 
eGFR; AF; Q waves; and LVH on ECG, plus prevalent 
stroke at baseline, as a cardiovascular disease associated 
with frailty. The fourth model added log- transformed 
IL-6 as an independent variable. IL-6, a proinflammatory 
cytokine, has been associated with incident HF risk.14 15
These analyses were repeated with the Fried scoring 
system, the Gill- like scoring system and the novel frailty 
score.
To demonstrate trends across groups, these analyses 
were repeated with the frailty groups assigned integer 
scores: 0–2 for the Fried (0=robust, 1=pre- frail, 2=frail) 
and Gill (0=non or mildly- frail, 1=moderately frail, 
2=severely frail) phenotypes and 0–3 for the novel score 
phenotypes. These were then modelled continuously as 
independent variables.
The proportional hazards assumption was tested by 
including interactions of the predictors and a function of 
survival time into the models. None of the time- dependent 
covariates were statistically significant, suggesting the 
proportional hazards assumption was not violated.
Supplementary analyses
Three further supplementary analyses were conducted: 
first, to examine the effect of early HF diagnoses during 
follow- up (which may indicate asymptomatic, or sympto-
matic, but un- diagnosed, HF), the analyses above were 
repeated, but excluding men who developed HF within 
2 years of baseline.
Second, we added baseline log NT- proBNP as an inde-
pendent variable to the fully adjusted main analysis. 
NT- pro- BNP is elevated in HF, and also a potent predictor 
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of incident HF16; adjusting for NT- pro- BNP levels at base-
line may, therefore, partially adjust for undiagnosed HF 
as a confounder.
Thirdl to determine the effect of our approach to 
missing values, we repeated the four stepwise analyses, 
restricted only to cases with complete data for the final 
(fully adjusted) model.
RESULTS
A total of 1722 men (55% of the surviving cohort) 
attended the baseline examination. A total of 111 men 
with prevalent HF and 166 men missing at least one 
frailty score were excluded, leaving 1445 men for analysis. 
A participant flow diagram is given in figure 1.
Baseline characteristics of participants
Table 1 gives baseline characteristics of participants. In 
bivariate analyses, mean age and NT- pro- BNP were signif-
icantly higher in the group that developed incident HF 
versus those who did not; mean FEV1 was significantly 
lower in those who developed incident HF. Men who 
developed incident HF were more likely to have had 
a prior MI, a prior stroke, to have Q waves on baseline 
Figure 1 Participant flow diagram. BRHS, British Regional 
Heart Study; GP, general practitioner; NHS, National health 
Service.
Table 1 Characteristics of study participants at baseline
Did not develop 
HF (n=1346)
Developed 
HF (n=99) P value
Age (years) 78.1 (4.5) 79.8 (4.9) 0.0004
Smoking status 0.42
  Never smoked 560 (38.6%) 34 (34.3%)
  Long- term ex- 
smoker
720 (53.5%) 55 (55.6%)
  Recent ex- smoker 62 (4.6%) 4 (4.0%)
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  Non- frail (0) 400 (29.7%) 18 (18.2%)
  Prefrail (1) 740 (55.0%) 62 (62.6%)
  Frail (2) 206 (15.3%) 19 (19.2%)
Gill- like score 0.32
Continued
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ECG, and to have AF than those who did not. There were 
significant differences in the proportions of men in the 
different Fried phenotype (p=0.047) and novel frailty 
score (p=0.013) groups between those with and without 
incident HF, but not in the proportions of those in the 
different Gill score groups (p=0.32).
Incident HF risk
Mean follow- up time was 6.1 years (SD 1.8 years). Table 2 
shows the rate of incident HF (per 1000 person- years) 
per frailty score group.
Figure 2 shows the results of Cox proportional hazard 
modelling of incident HF risk for all three frailty 
scoring systems, with progressive adjustment for likely 
confounders.
Men who were prefrail or frail, as defined by the Fried 
phenotype, showed a non- statistically significant associa-
tion with HF risk (HR 1.68, 95% CI 0.99 to 1.92, p=0.05 and 
HR 1.92, 95% CI 0.99 to 3.73, p=0.05, respectively). 
Adjustment for prevalent MI and BMI attenuated the 
association, as did further adjustment for clinical param-
eters. When modelled continuously for trend, there was a 
significant association between higher Fried frailty score 
and risk of incident HF in the model adjusting for age 
only (HR 1.38, 95% CI 1.01 to 1.89, p=0.04) but not with 
subsequent adjustments.
There were no significant differences in HF risk 
between non- frail or mildly frail men and moderately 
or severely frail men as defined by the Gill- like score in 
any of the models, nor when the scores were modelled 
continuously.
Men with the highest novel frail score had a higher HF 
risk compared with those in the lowest group in the age- 
adjusted model (HR 2.77, 95% CI 1.25 to 6.15, p=0.01), 
which persisted after adjusting for prevalent MI and BMI 
(HR 2.55, 95% CI 1.14 to 5.72, p=0.02), additional clin-
ical risk factors (HR 3.06 95% CI 1.31 to 7.14, p=0.01) and 
after adjustment for log IL-6 (HR 3.14, 95% CI 1.35 to 
7.31, p=0.008). When modelling the frailty severity score 
continuously for trend, there were statistically significant 
associations between higher novel frailty scores and inci-
dent HF risk in all analyses (HR 1.37, 95% CI 1.07 to 1.76, 
p=0.01 in the fully adjusted model).
Supplementary analyses
The results of a supplementary analysis, excluding 23 
participants who developed incident HF within 2 years 
of the baseline examination, are given in table 3—for 
brevity, only the age- adjusted and fully adjusted models 
are given. Most associations were notably weaker than in 
the main analyses. The association between HF risk and 
the top group of the novel frailty score lost significance, 
but those in the second- highest group had a significant 
positive association with HF risk (age adjusted, HR 2.70, 
95% CI 1.29 to 5.62, p=0.008), which was retained after 
full adjustment (HR 2.24, 95% CI 1.02 to 4.95, p=0.05).
Adding log- NT- pro- BNP to the fully- adjusted models 
weakened the association between HF and the highest 
group of the novel frailty score slightly (HR 2.92, 95% CI 
1.23 to 6.95, p=0.02); associations between the other 
scores and incident HF were already non- significant 
and did not appreciably change from those given in 
figure 2.
Repeating the first three stepwise main analyses using 
complete case data only (n=1289) did not materially 
change the strengths of the associations reported in 
figure 2.
Did not develop 
HF (n=1346)
Developed 
HF (n=99) P value
  Mild or no frailty 
(0)
1212 (90.0%) 85 (85.9%)
  Moderate frailty (1) 97 (7.2%) 9 (9.1%)
  Severe frailty (2) 37 (2.8%) 5 (5.1%)
Novel frailty score 0.013
  0 967 (71.8%) 57 (57.6%)
  1 260 (19.3%) 26 (26.3%)
  2 76 (5.7%) 9 (9.1%)
  3 43 (3.2%) 7 (7.1%)
For normally distributed continuous variables, values are mean 
(SD) and p values for t tests; for NT- pro- BNP and interleukin-6, 
values are geometric mean (IQR) and p values for Kruskall- Wallis 
tests; for categorical variables values are N (% of total by column) 
and p values for χ2 tests.
HF, heart failure; NT- proBNP, N- terminal pro B- type natriuretic 
peptide.
Table 1 Continued
Table 2 Incident rates of HF per 1000 person- years for 
participants in each frailty score group





  Non- frail (n=418) 18 6.60
  Prefrail (n=802) 62 12.1
  Frail (n=225) 19 15.8
Gill- like score
  Non- frail or mildly frail 
(n=1297)
85 10.5
  Moderate frailty (n=106) 9 16.2
  Severe frailty (n=42) 5 24.4
Novel frailty score
  0 (n=1024) 57 8.82
  1 (n=286) 26 15.1
  2 (n=85) 9 20.6
  3 (n=50) 7 29.5
HF, heart failure.
by copyright.
 on June 16, 2021 at S
t G
eorge's U












6 McKechnie DGJ, et al. Open Heart 2021;8:e001571. doi:10.1136/openhrt-2021-001571
DISCUSSION
Summary
In this cohort of older men, we found an association 
between frailty—as measured by a novel score combining 
low gait speed, slow sit- stand time and subjective balance 
impairment—and incident HF risk, that persisted despite 
adjustment for comorbidities, known risk factors for HF 
and biomarkers of inflammation. The Fried frailty pheno-
type had a non- significant association with increased HF 
risk in age- adjusted analysis, and this was attenuated 
further after adjustment for BMI and prevalent MI. By 
contrast, we found no association between our approxi-
mation of the Gill index and incident HF.
The three scores assess different features of frailty. Our 
novel score incorporated sit- stand time and gait speed, 
both determined by lower limb muscle strength (itself 
reflecting sarcopenia17), but also sensorimotor, balance 
and psychological factors.18 19 We also included subjec-
tive balance difficulties, a complex construct which 
relates to lower limb strength, peripheral and vestib-
ular sensation,20 and central sensorimotor integration 
and control.21 Poor performance in all of these areas 
was associated with a significantly higher HF risk. This 
accords with findings that HABC battery score (relating 
to balance, gait speed and chair- stand) predicted inci-
dent HF.7
Figure 2 Cox proportional hazard modelling of risk of incident heart failure. ’Further risk factors’ are prevalent stroke, systolic 
blood pressure, smoking status, use of blood pressure lowering medications, EGFR, FEV1, atrial fibrillation, Q waves, and 
left ventricular hypertrophy. analyses are presented first with comparisons with the reference (robust/least frail) modelled as 
categorical variables, then trend across groups modelled as continuous variables. BMI, body mass index; EGFR, estimated 
glomerular filtration rate; FEV1, forced expiratory volume in 1 s.
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A weaker association was seen between HF risk and 
the Fried phenotype, which includes gait speed, but also 
grip strength (dependent on upper- limb muscle power), 
reduced physical activity, unintentional weight loss and 
exhaustion (which may reflect reduced energy produc-
tion, increased energy demand and sarcopenia, but are 
potentially influenced by comorbidities). Gait speed and 
balance (as in the novel score) may relate more closely to 
incident HF than other aspects of the Fried phenotype. 
Weight loss (‘cardiac cachexia’) and exhaustion are seen 
in established HF, but may be consequences of the illness, 
rather than heralds of it.
We found no association between our approxima-
tion of the Gill index and incident HF risk, contrasting 
with prior work.7 While the Gill index shares two 
parameters with our novel score (gait speed and 
chair- stand, though the scoring of the latter differs), 
it lacks assessment of balance. Balance (and its 
underlying determinants) may be more important in 
determining HF risk. The majority (90%) of men for 
whom we could calculate this score were identified as 
non- frail or mildly frail, which may have limited its 
discriminant ability in this sample. Our calculation of 
a ‘Gill- like’ score was not identical to the original Gill 
index, so we cannot refute an association between the 
Gill index and incident HF. The smaller numbers in 
our study vs the HABC study7 (n=1289 vs n=2825) may 
also have been under- powered to detect a statistically 
significant association with the Gill score.
Frail participants may have had asymptomatic, or 
symptomatic but undiagnosed, HF at baseline. We ran 
two sensitivity analyses to investigate this possibility. 
Adjusting for NT- pro- BNP—which is elevated in HF—
at baseline made little difference to the association 
between the novel score and incident HF. In a supple-
mentary analysis, excluding incident HF events within 
2 years of baseline, the associations between HF risk 
and the top group in the novel score were attenuated, 
but remained increased (although non- statistically 
significant). A statistically significant association with 
HF risk was seen in the second- highest group in all 
analyses. However, because of the small number of 
cases involved after exclusion, it is difficult to draw 
firm conclusions from this supplementary analysis. We 
cannot rule out the possibility of reverse causation.
Strengths and limitations
Our study has a relatively long and complete follow- up, 
with multiple baseline assessments, allowing adjustment 
for many potential confounders. We assessed differential 
associations between three different measures of frailty 
status. These frailty scores are straightforward to calculate 
and easy to replicate in research and clinical practice.
The novel frailty score used in this study was construed 
as an approximation of the HABC battery score; as both 
measures are associated with HF risk in two different 
cohorts, this suggests that they are both testing similar 
underlying concepts and our novel score may have some 
external validity. However, our novel frailty score has 
not been formally validated as a frailty scoring tool, and 
therefore cannot be used without further validation.
Table 3 Results of Cox proportional hazard modelling 
of risk of incident heart failure, in a subgroup analysis 
excluding HF events within 2 years of baseline
HR 95% CI of HR P value
Fried phenotype
Adjusted for age only (n=1422)
  Prefrail vs non- frail 1.64 0.91 to 2.94 0.10
  Frail vs non- frail 1.59 0.73 to 3.47 0.24
  Modelled continuously 
for trend
1.28 0.90 to 1.84 0.17
Fully adjusted* (n=1268)
  Prefrail vs non- frail 1.44 0.78 to 2.67 0.25
  Frail vs non- frail 1.15 0.49 to 2.69 0.75
  Modelled continuously 
for trend
1.10 0.75 to 1.62 0.63
Gill- like score
Adjusted for age only (n=1422)
  Moderate vs mild/no 
frailty
1.18 0.51 to 2.75 0.70
  Severe vs mild/no frailty 1.68 0.52 to 5.37 0.38
  Modelled continuously 
for trend
1.26 0.76 to 2.08 0.80
Fully adjusted* (n=1268)
  Moderate vs mild/no 
frailty
1.25 0.52 to 2.98 0.62
  Severe vs mild/no frailty 0.92 0.22 to 3.88 0.90
  Modelled continuously 
for trend
1.03 0.59 to 1.80 0.93
Novel frailty score
Adjusted for age only (n=1422)
  1 vs 0 1.43 0.83 to 2.46 0.20
  2 vs 0 2.70 1.29 to 5.62 0.008
  3 vs 0 1.69 0.52 to 5.49 0.38
  Modelled continuously 
for trend
1.38 1.06 to 1.79 0.02
Fully adjusted* (n=1268)
  1 vs 0 1.15 0.64 to 2.07 0.93
  2 vs 0 2.24 1.02 to 4.95 0.05
  3 vs 0 2.05 0.61 to 6.92 0.25
  Modelled continuously 
for trend
1.34 1.00 to 1.80 0.05
*Fully adjusted=adjusted for age, prevalent myocardial infarction, 
prevalent stroke, systolic blood pressure, smoking status, use 
of blood pressure lowering medications, eGFR, FEV1, atrial 
fibrillation, left ventricular hypertrophy, Q waves and log IL-6.
eGFR, estimated glomerular filtration rate; FEV1, forced expiratory 
volume in 1 s; IL-6, interleukin-6.
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It is possible that residual confounding and reverse 
causation remains. Although we adjusted for NT- pro- BNP 
in a sensitivity analysis, we lacked echocardiographic data 
at the entry examination; some individuals may have 
had subclinical HF. Our sensitivity analysis excluding 
HF cases within 2 years suggests that the associations 
between frailty and HF risk may still have been biased by 
undiagnosed HF at baseline, though this was based on 
smaller numbers. Our definition of incident HF relied 
on physician- diagnosed HF, which may underestimate 
the true burden of incident HF, although associations 
between this outcome and HF risk factors reported 
in our prior work generally accord with prior data22 23 
suggesting external validity. While we attempted to adjust 
for the effects of AF, ischaemic heart disease, myocardial 
damage (as signified by Q waves), stroke and LVH at base-
line (all of which are associated with HF risk), our sample 
size precluded removing these patients from the analyses 
entirely. ECG determinants of LVH tend to have poor 
sensitivity (although good specificity)24 and therefore 
more sensitive methods—such as cardiac imaging—may 
identify more undiagnosed cases of LVH in our sample.
Frailty is strongly associated with all- cause mortality,25 
which may lead to survivorship bias: frail men may have 
died earlier from alternative causes and without HF. Frail 
men from the original cohort may have been less likely 
to attend the baseline examination and therefore more 
likely to have been excluded from the analyses. Both of 
these biases would be expected to weaken associations 
between incident HF and frailty.
We were unable to determine the HF subtype of those 
who developed incident HF; HF with reduced ejection 
fraction and HF with preserved ejection fraction may 
present with similar clinical features, but are likely to 
have different underlying pathophysiology26 and may 
show differential associations with frailty.4 The ‘novel 
frailty score’ used here incorporated a subjective measure 
of balance and may be confounded by multimorbidity. 
Our cohort was male and almost entirely of White origin, 
which may limit the generalisability of the findings to 
women and people of other ethnic groups.
Implications for future research
Further longitudinal studies should report on the rela-
tionship between prevalent frailty and incident HF. 
Future work should include different frailty measures and 
should attempt to replicate the strong association seen 
here between low walk speed, slow chair- stand time, diffi-
culties with balance and incident HF in other cohorts. 
This association appeared to be independent of known 
risk factors and inflammation, and so could provide valu-
able insights into novel mechanisms linking frailty and 
HF. It could also be developed as a prediction tool for 
HF risk.
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